$9.87
-1.8%ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Chief Financial Officer
Director of Finance & Administration and Controller
Director of Product Development
President, Chief Executive Officer, Treasurer, Secretary & Director
Compensation
$392,609
Senior Director of Quality
Vice President of Sales & Marketing and Director
Compensation
$364,403
During the last 12 months, insiders have purchased $56K and sold $149K worth of ICCC shares, resulting in $94K of net selling activity.
0
0.00
25.3K
149.44K
-149K
-$149K
0
0.00
0
0.00
+0
+$0
9.6K
49.27K
0
0.00
+49K
+$49K
1.0K
6.32K
3
14.00
+6K
+$6K
Te Boekhorst Paul Francis Olivier
Director, Officer: President And Ceo
$49K
Gathagan Bryan K.
Director
$6K
Te Boekhorst Paul Francis Olivier
Director, Officer: President And Ceo
$149K
Basse Gloria F
Director
$14
Negative insider sentiment with $94K net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Weak buy/sell ratio. Selling significantly exceeds buyingโmonitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
2 insider buyers and 2 sellers. Equal participation suggests mixed or neutral insider views.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
ICCC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 10, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 13, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 14, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.